Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - 1 Nov 2023

Wu Shannon S, Lamarre Eric D, Scharpf Joseph, Prendes Brandon, Ku Jamie A, Silver Natalie, Burkey Brian, Woody Neil, Campbell Shauna R, Yilmaz Emrullah, Koyfman Shlomo A, Geiger Jessica

Abstract excerpt

OBJECTIVE: Small molecule inhibitors (SMIs) are targeted therapies increasingly used in advanced thyroid carcinomas. This study aimed to evaluate the survival outcomes of thyroid cancer on SMI treatment, including in patients with brain metastases. METHODS: This retrospective study included patients with thyroid carcinomas who received at least one SMI between 2008 and 2022 at a tertiary level, academic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 37597577
DOI: 10.1016/j.eprac.2023.08.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors.PMID 37597577Read ↗

Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer.Semantic proximity Read ↗

Clinical and genomic characterization of brain metastasis in thyroid cancer.Semantic proximity Read ↗

Thyroid Carcinoma Brain Metastases: Radiosurgery Outcomes and Genomic Characterization Across Histologic SubtypesSemantic proximity Read ↗

Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.Semantic proximity Read ↗

Brain Metastases from Thyroid Carcinoma: Prognostic Factors and OutcomeSemantic proximity Read ↗

Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.Semantic proximity Read ↗

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.Semantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.Semantic proximity Read ↗

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.